Navigation Links
Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
Date:11/7/2011

t candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
2. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
5. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
6. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
7. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
10. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
11. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of version 5.2 of the FirstSpirit Content Management System with ... initiative. With the new version of FirstSpirit, companies will be well on their ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Zecurion, a leading ... , its groundbreaking new version of endpoint DLP developed specifically for Mac OS. , ... which more than 100 IT and information security professionals had participated. The beta test ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Agriculture innovation, urban farming, ... of the topics to be discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference ... UC San Diego. , In addition to keynotes Pierre Sleiman, founder and CEO ...
(Date:9/1/2015)... ... 2015 , ... METTLER TOLEDO has announced an upcoming webinar ... , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This webinar ... , Calibration, qualification, and the appropriate level of routine testing for laboratory instruments ...
Breaking Medicine News(10 mins):Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... WHO: Martin Payne, Executive Vice President, Sales ... Leigh Hocker Radtke, Director, Software Product Management, SkyeTek, ... 2:00 PM - 3:00 PM EDT, ... DESCRIPTION: Medical sales processes are becoming increasingly complex,due to changes ...
... BETHLEHEM, Pa., June 24 At this year,s ... Inc. and its MIKE AND,IKE(R) Candy Brand presented ... the first in a multi-year commitment to this ... MIKE AND IKE(R) Lemonade Blends(TM) kicks off Just ...
... today announced the signing of a distribution agreement ... will enhance selling,efforts for Hill-Rom,s product The Vest(R) ... facilities within the United States., "We are ... Kim,Dennis, group vice president, Post Acute Care at ...
... Fla., June 24 Synovics,Pharmaceuticals, Inc. (OTC ... announced that its wholly owned subsidiary,ANDAPharm, LLC ... pharmaceutical,company for the manufacturing and supply of ... by ANDAPharm with this product, including an,earlier ...
... authored by a University of Queensland academic has ... key factors in the transmission of MRSA (Meticillin ... Dr Archie Clements, from the School of Population ... MRSA infections, which lead to increased inpatient hospital ...
... busy units, even basic hand-washing can get lost in ... 24 (HealthDay News) -- Overcrowding and understaffing can cause ... aureus (MRSA) in hospitals, Australian researchers report. ... Health, University of Queensland, noted that hospitals in many ...
Cached Medicine News:Health News:SkyeTek to Host Webinar Discussing RFID-Based Solution for Medical Sales Processes Automation 2Health News:MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alex's Lemonade Stand Foundation 2Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 2Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 3Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 4Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 2Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 3Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 4Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 5Health News:Overcrowding and understaffing in hospitals increases levels of MRSA infections 2Health News:MRSA Rates Tied to Hospital Understaffing 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: